Cargando…

Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo

OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenguang, Yu, Lin, Gu, Pengfei, Bo, Ruonan, Xu, Shuwen, Wusiman, Adelijiang, Liu, Jiaguo, Hu, Yuanliang, Wang, Deyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650836/
https://www.ncbi.nlm.nih.gov/pubmed/33177820
http://dx.doi.org/10.2147/IJN.S266165
_version_ 1783607565790216192
author Liu, Zhenguang
Yu, Lin
Gu, Pengfei
Bo, Ruonan
Xu, Shuwen
Wusiman, Adelijiang
Liu, Jiaguo
Hu, Yuanliang
Wang, Deyun
author_facet Liu, Zhenguang
Yu, Lin
Gu, Pengfei
Bo, Ruonan
Xu, Shuwen
Wusiman, Adelijiang
Liu, Jiaguo
Hu, Yuanliang
Wang, Deyun
author_sort Liu, Zhenguang
collection PubMed
description OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the effects of surface chemistry on the adjuvant activity of Ganoderma lucidum polysaccharide cubosomes (GLPC) by placing two kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB) and poly(diallydimethyl ammonium chloride) (PDDAC), on their surface. RESULTS: CTAB- or PDDAC-modified GLPC were found to significantly promote humoral and cellular immune responses, as well as the proliferation of CD3+ CD4+ or CD3+ CD8+T cells through the powerful activation of dendritic cells (DCs). The enhanced immune responses of PDDAC-modified GLPC might be attributed to the maturation of DCs into draining lymph nodes and the activation of spleen and cytokines in serum. CONCLUSION: PDDAC modification is beneficial for enhancing humoral and cellular immune response, suggesting that PDDAC-GLPC-OVA has the ability to be a potential adjuvant for vaccine.
format Online
Article
Text
id pubmed-7650836
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76508362020-11-10 Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo Liu, Zhenguang Yu, Lin Gu, Pengfei Bo, Ruonan Xu, Shuwen Wusiman, Adelijiang Liu, Jiaguo Hu, Yuanliang Wang, Deyun Int J Nanomedicine Original Research OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the effects of surface chemistry on the adjuvant activity of Ganoderma lucidum polysaccharide cubosomes (GLPC) by placing two kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB) and poly(diallydimethyl ammonium chloride) (PDDAC), on their surface. RESULTS: CTAB- or PDDAC-modified GLPC were found to significantly promote humoral and cellular immune responses, as well as the proliferation of CD3+ CD4+ or CD3+ CD8+T cells through the powerful activation of dendritic cells (DCs). The enhanced immune responses of PDDAC-modified GLPC might be attributed to the maturation of DCs into draining lymph nodes and the activation of spleen and cytokines in serum. CONCLUSION: PDDAC modification is beneficial for enhancing humoral and cellular immune response, suggesting that PDDAC-GLPC-OVA has the ability to be a potential adjuvant for vaccine. Dove 2020-11-04 /pmc/articles/PMC7650836/ /pubmed/33177820 http://dx.doi.org/10.2147/IJN.S266165 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Zhenguang
Yu, Lin
Gu, Pengfei
Bo, Ruonan
Xu, Shuwen
Wusiman, Adelijiang
Liu, Jiaguo
Hu, Yuanliang
Wang, Deyun
Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title_full Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title_fullStr Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title_full_unstemmed Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title_short Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
title_sort surface-engineered cubosomes serve as a novel vaccine adjuvant to modulate innate immunity and improve adaptive immunity in vivo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650836/
https://www.ncbi.nlm.nih.gov/pubmed/33177820
http://dx.doi.org/10.2147/IJN.S266165
work_keys_str_mv AT liuzhenguang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT yulin surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT gupengfei surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT boruonan surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT xushuwen surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT wusimanadelijiang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT liujiaguo surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT huyuanliang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo
AT wangdeyun surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo